The Effect of CytoSorb on Inflammatory Markers in Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

ABSTRACT:

Objectives

The effectiveness of CytoSorb at removing inflammatory mediators in critically ill patients is controversial.

Data sources

Electronic databases were searched from inception to May 2023.

Study selection

Randomized controlled trials reporting the effects of CytoSorb therapy on inflammatory parameters in critically ill patients with hyperinflammatory conditions were included.

Data extraction

Two authors screened articles for eligibility, extracted data, and assessed the risk of bias, conflicts of interest, and certainty of evidence (CoE). The primary outcome was interleukin (IL)-6 at 1 day after initiation of the therapy. Secondary outcomes included various inflammatory markers at 1, 2, 3, and 5 days and mortality. Data were pooled if at least three tri

SUBMITTER: Heymann M 

PROVIDER: S-EPMC10645103 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature